TMS and Spravato Prior Authorization: What Payers Require in 2026

Prior authorization for TMS and Spravato requires field-level documentation precision that many practices underestimate.

Prior authorization denial rates for TMS and Spravato reach 35% among behavioral health practices that submit without complete step-therapy documentation, based on workflow data from HelpSquad's billing support team compiled through 2025. Both treatments share a common vulnerability: payers approve them only after a practice proves the patient exhausted standard antidepressant options, and the proof requirements are precise. One missing date on a failed drug trial can stop a $10,000 TMS course before it starts.

I spent four years supporting UnitedHealth Group claims operations before joining HelpSquad, and I watched the same documentation gap trigger the same denial hundreds of times. Practices knew the clinical story. They just did not know that payers were hunting for specific fields, not narrative summaries. That operational experience shapes everything I will cover in this guide.

What follows covers what the six largest payers require for TMS and Spravato prior authorization in 2026, why the Spravato REMS program adds a layer most practices underestimate, and where a trained virtual assistant can carry the documentation load without crossing into clinical territory that only your prescriber can own.

What Every Major Payer Wants Before Approving TMS in 2026

The core requirement for TMS prior authorization has not changed: payers want documented proof that the patient tried and failed conventional antidepressant treatment. What has changed is how precisely that proof must be structured, and how little tolerance automated payer systems now have for missing fields.

Here is what the six largest payers required for TMS authorization as of mid-2026:

The table makes requirements look uniform. In practice, documentation format matters as much as clinical facts. From what I saw during four years with Optum's claims processing team, the single most common trigger for a technical denial was a medication trial listed with a start date but no end date, or vice versa. The payer's system could not confirm the trial lasted six weeks, so it rejected the request automatically, before a clinical reviewer ever touched the file.

The Documentation Fields That Stop Denials

For each failed antidepressant trial, your PA submission needs all of the following:

• Drug name (generic and brand where possible)
• Start date (exact or approximate month and year)
• End date (exact or approximate month and year)
• Dose in milligrams, confirming it reached therapeutic range
• Reason for discontinuation (inadequate response is what most payers require)
• Prescribing provider name and NPI

That last field matters more than most people expect. Aetna and UHC have both flagged submissions where the prescribing NPI on the failed trial history did not match any provider in the payer's records, even when the original prescriber was legitimately out-of-network. Include the prescriber's name, NPI, and specialty alongside each listed trial.

Why "Inadequate Response" Beats "Side Effects" in the Documentation

Most payer coverage policies specify that the failed trials must have ended due to inadequate therapeutic response, not solely due to side effects or tolerability issues. This distinction is KEY. If your documentation states that a patient stopped sertraline because of GI side effects, some payers will require an additional trial as a substitute. The clinical story may be accurate, but the documentation frames it as a tolerability stop, not a treatment failure.

I would recommend reviewing each listed trial with your prescriber before submission and confirming that the reason-for-discontinuation language aligns with payer expectations. A VA can prepare a draft summary that the prescriber reviews and affirms. The VA writes the structure; the clinician confirms the framing. That is the correct division of labor for this step.

What Will Matter Most in TMS and Spravato PA Over the Next 12 to 24 Months

The prior authorization landscape for behavioral health treatments is shifting, and practices with TMS and Spravato volume should watch four trends closely over the next two years.

Federal PA Reform Is Compressing Decision Timelines

The CMS final rule on prior authorization, published in January 2024 with compliance phases running through 2027, requires Medicare Advantage plans, Medicaid managed care, and CHIP plans to respond to urgent PA requests within 72 hours and standard requests within seven calendar days. Commercial payers face parallel pressure from state-level reforms in 20 or more states as of 2025.

For TMS and Spravato practices, faster payer decisions mean more automated, system-driven outcomes with less tolerance for documentation gaps. A submission that might have survived human clinical review may now be denied by an automated rule that flags a missing field. Shorter response windows require greater accuracy on the first submission, not just faster submission.

Gold Carding Programs May Reduce PA Burden for High-Volume Practices

Some payers are implementing gold carding programs that waive PA requirements for providers with a documented history of appropriate prescribing. Several state legislatures passed gold carding mandates in 2024 and 2025, with more under active consideration. Practices that maintain clean PA records and low denial rates are best positioned to qualify.

If your practice submits 20 or more TMS or Spravato PAs per year, it is worth asking your payer representatives whether a gold carding arrangement is available. The compliance record you build now directly affects your eligibility for streamlined access later. Both the 35% denial rate and the 50% appeal overturn rate in HelpSquad's workflow data suggest significant room for most practices to improve that record.

AI Is Being Deployed on Both Sides of the PA Transaction

Payers are deploying AI tools to score PA submissions for completeness and flag incomplete requests before a clinical reviewer sees them. Practices are beginning to use AI tools to automate form completion and documentation gathering. Both sides benefit when the underlying documentation is accurate. Speed without accuracy adds denial rate, not efficiency. The practices that benefit from AI-assisted PA preparation are the ones that verify output before submitting it.

Spravato's Evidence Base Is Growing, Which May Ease Some Requirements

Post-approval real-world evidence for Spravato has been building since the 2019 FDA approval. Several major payers reviewed Spravato coverage criteria in 2024 and 2025 and adjusted required failed trial counts based on new clinical data. Some plans moved from three required prior failures to two. This is a positive trend for patient access, but it is payer-specific. Do not assume a coverage update at one plan applies to another. Check each payer's current policy within 90 days of submitting a new PA, since coverage changes are rarely announced directly to practices.

How Spravato PA Differs: REMS, Concurrent Medications, and Site Requirements

Spravato (esketamine) carries prior authorization requirements that most practices do not anticipate when they first encounter it. TMS prior authorization is demanding because of documentation precision. Spravato is demanding because of regulatory and clinical requirements that go beyond paperwork entirely.

The REMS Requirement Is Non-Negotiable

Spravato is subject to a Risk Evaluation and Mitigation Strategy (REMS) program mandated by the FDA. Every healthcare setting that administers Spravato must be certified through the REMS program, and that certification must be active and documented in your PA submission. Payers cross-check the administering facility against the REMS registry. If your facility's REMS certification has lapsed or was never completed, the PA will be denied before clinical criteria are evaluated.

REMS certification must be renewed annually. In HelpSquad's experience supporting behavioral health PA workflows, lapsed REMS certification is the second most common Spravato PA denial trigger, right behind missing step-therapy documentation. It is a purely administrative compliance issue, fully preventable with a calendar reminder and a VA tracking renewal dates ahead of the expiration.

The Concurrent Oral Antidepressant Rule

All major payers require that Spravato be used in conjunction with a current oral antidepressant. This is an FDA label requirement as well as a payer requirement. Your PA documentation must show:

• The name of the concurrent oral antidepressant the patient is actively taking
• Dose and duration of that current regimen
• Why the current regimen alone is insufficient, establishing the treatment-resistant depression diagnosis

A practice that submits a Spravato PA without clearly identifying the concurrent oral medication will typically receive a request for additional information, adding 7 to 14 days to the approval timeline per cycle. For a patient in active crisis, that delay carries real clinical weight.

Payer-Specific Spravato Requirements in 2026

The 2-Hour Observation Requirement and Why It Affects Billing

After each Spravato administration, the patient must be observed for a minimum of two hours. This is a REMS requirement, not only a payer requirement, and it affects how you structure billing and staffing. Supervising clinical staff cannot leave the patient unmonitored during this window.

From a billing standpoint, the observation period is typically coded with an evaluation and management (E&M) code alongside the Spravato administration code. Some practices miss the E&M component entirely, which reduces reimbursement and, in some payer audits, raises questions about whether REMS protocols were actually followed. It's important to note that Spravato cannot be dispensed for home use under any circumstances. Payers verify this through site-of-service codes on claims, and a mismatch between the PA-approved site and the claim's site-of-service code triggers a post-payment audit.

What a Virtual Assistant Can Own in the PA Process (and What Only the Prescriber Can Sign)

This is the question I hear most often from practices considering outsourced PA support for TMS and Spravato. There is a clear dividing line, and understanding it protects your practice from both compliance risk and unnecessary process delays.

What a Trained VA Can Legally Handle

A virtual assistant working under appropriate supervision can own the following parts of the PA workflow:

• Documentation gathering: Compiling treatment history, pulling medication trial records, collecting exact dates and dosages from the patient chart or prior provider records
• PA form completion: Entering all non-clinical fields, populating diagnosis codes, procedure codes, provider NPIs, and facility credentials
• REMS verification: Confirming that the facility's REMS certification is current and active before submission
• Submission and follow-up: Submitting the PA through the payer portal or by phone, tracking status, and responding to requests for additional information
• Appeal letter drafting: Drafting written appeal submissions and peer-to-peer preparation materials based on clinical notes the prescriber provides
• Denial analysis: Identifying the specific denial reason code and flagging what additional documentation is needed to resolve it
• Status tracking and escalation: Monitoring PA timelines and escalating to the clinical team when a peer-to-peer review is required

What Only the Prescriber Can Sign or Attest

The clinical record is the prescriber's domain. A VA cannot create, alter, or attest to clinical documentation including the letter of medical necessity. A VA cannot make clinical judgments about a patient's treatment history, conduct or represent a peer-to-peer review, sign any document submitted to the payer under the provider's NPI, or independently determine which ICD-10 diagnosis code applies.

In practice, the most efficient model I have seen is a VA who prepares everything: a draft letter of medical necessity, a completed PA form with every field populated, a checklist of required supporting documents. The prescriber reviews the complete package, confirms clinical accuracy, and signs. Clinical time stays reserved for clinical review, not data entry. That is the QA mindset applied to healthcare administration: define scope precisely, assign tasks to the correct tier, and review at the boundary between them.

Handling Denials and Appeals

Approximately 50% of initial TMS and Spravato PA denials are overturned on first-level appeal when the practice submits complete documentation, based on HelpSquad's internal tracking across behavioral health clients through 2025. The reason most denials get overturned is straightforward: the original submission was missing a field the payer required, and the appeal fills that gap.

The appeal process varies by payer, but the general structure is consistent:

1. First-level written appeal: Submitted within 30 to 60 days of denial (payer-specific deadline). Include all original documentation plus a targeted response to the specific denial reason code.
2. Peer-to-peer review: Most payers offer this for TMS and Spravato. The treating clinician speaks directly with the payer's medical reviewer. Success rates are high when the treating physician comes prepared with the patient's specific trial history and clinical rationale.
3. Independent external review: Available in most states for medical necessity denials and required for plans subject to state insurance regulation.

A VA can prepare the complete appeal package for steps one and three. Step two requires the prescriber's direct participation. The VA's job is to make that conversation as short and productive as possible by ensuring every supporting document is ready before the call begins.

Prior authorization for TMS and Spravato is not going to get simpler. Federal reform is compressing response timelines, and automated denial systems have less tolerance for documentation gaps than the human reviewers they are replacing. The practices that manage this well are not necessarily the ones with the most clinical complexity. They are the ones with the most organized administrative process.

The dividing line between what a VA can own and what only the prescriber can sign is the key to building that process efficiently. A trained VA prepares everything. The prescriber reviews and attests. That division of labor protects compliance and reserves clinical time for work that actually requires a clinician.

If your practice manages TMS or Spravato volume and is running into denial rates above 20%, the problem is almost always in the documentation, not the clinical record. HelpSquad's virtual assistants are trained specifically on behavioral health PA workflows, including TMS and Spravato documentation requirements, REMS compliance tracking, and appeal preparation. Reach out to discuss what a managed PA process looks like for your practice.